May 3, 2027 — May 5, 2027
Bioethics International & EY’s 18th Annual Pharmaceutical Executive Roundtable on Ethics, Trust + Patient Centricity in Pharma. New York City.
The event date will be earlier next year on May 3rd, 4th or 5th. We will finalize soon.
The Roundtable is co-hosted with Yale Medicines Access Network (YMAN), Yale Program for Biomedical Ethics, and Scientific American.
This annual roundtable is the leading forum for senior leaders in healthcare, including industry, patient groups, and academia, to discuss the state of bioethics and patient centricity in medicine development and access and the role of the pharmaceutical sector.
August 11, 2026
May 3, 2027 — May 5, 2027
Bioethics International & EY’s 18th Annual Pharmaceutical Executive Roundtable on Ethics, Trust + Patient Centricity in Pharma. New York City.
The event date will be earlier next year on May 3rd, 4th or 5th. We will finalize soon.
The Roundtable is co-hosted with Yale Medicines Access Network (YMAN), Yale Program for Biomedical Ethics, and Scientific American.
This annual roundtable is the leading forum for senior leaders in healthcare, including industry, patient groups, and academia, to discuss the state of bioethics and patient centricity in medicine development and access and the role of the pharmaceutical sector.
Bridging the Gap Between Clinical Trials and Access: Launching the Yale Medicines Access Network (YMAN) Across the globe, patients in low- and middle-income countries (LMICs) are increasingly participating in clinical trials that support regulatory approvals of novel medicines. Yet too often, once those medicines are approved—particularly by the U.S. Food and Drug Administration (FDA)—they remain…
April 6, 2026
When countries hosts clinical trials for new medicines and vaccines, most of us assume patients there will eventually benefit from the products they helped test. According to the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) guidelines, populations who bear the burdens of research should share in its benefits.Our new study…
January 6, 2026
30% of new drugs are not adequately tested in women. BBC Discovery, with Dr Ella Hubber & Chhavi Sachdev & Jennifer Miller, explores how women have been historically excluded from clinical trials, why biological differences matter in how drugs work, and how this can lead to higher rates of side effects.
They also ask what change can look like: more representative trials, pharmaceutical companies held accountable, the role of the Good Pharma Scorecard in ensuring medicine is built for everyone.
Listen here: Discovery – Women Not Included: Drugs and clinical trials – BBC Sounds
Key Points
Question Are medicines physically accessible in the countries where they are tested for US Food and Drug Administration (FDA) approval, and has physical access improved over time?
Findings In this cross-sectional study of 172 medicines approved by the FDA from 2015 to 2018 and tested in 89 countries, 24% were physically accessible in all countries where they were tested 5 years after FDA approval. Countries in Western Europe had notably better access (82%) than countries in Africa (28%), with no improvements over time for low- and middle-income countries.
Meaning Most countries participating in trials for FDA approvals cannot physically access the medicines they test, particularly low- and middle-income countries, raising exploitation concerns, with no improvements over time.
Importance Populations participating in clinical trials should stand to benefit from resulting interventions, according to ethical guidance. Yet, our studies show low- and middle-income countries (LMICs) participating in trials for US Food and Drug Administration (FDA) approvals lack timely access to the medicines they help test, raising exploitation concerns.
See full study in JAMA IM here.
